ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose-Ranging Trial of Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01601210
Recruitment Status : Completed
First Posted : May 17, 2012
Last Update Posted : October 25, 2016
Sponsor:
Information provided by (Responsible Party):
Perry Renshaw, University of Utah

Brief Summary:

The purpose of this study is to see if creatine, which is a naturally occurring chemical in the body, is effective for treating Major Depressive Disorder (MDD) in female teenagers.

The primary hypothesis is that compared to placebo, 2g, 4g, and 10g of creatine monohydrate for eight weeks will be associated with a significant increase in brain phosphocreatine (PCr) concentrations.


Condition or disease Intervention/treatment Phase
Major Depressive Disorder Drug: Creatine monohydrate or placebo Early Phase 1

Detailed Description:

The purpose of this study is to see if creatine, which is a naturally occurring chemical in the body, is effective for treating Major Depressive Disorder (MDD) in female teenagers. Creatine may have effects of interest in the brain. The reason for the MRI component of this study is to learn about new ways to see inside the brain. The investigators will use magnetic fields and radio waves to look at the brain and chemicals in the brain. The investigators hope that this technique will have medial use in the future.

The primary hypothesis is that compared to placebo, 2g, 4g, and 10g of creatine monohydrate for eight weeks will be associated with a significant increase in brain phosphocreatine (PCr) concentrations. A secondary hypothesis is that decreased depressive symptoms measured with the Children Depression Rating Scale-Revised (CDRS-R) and Montgomery Asberg Depression Rating Scale (MADRS) will be reciprocally correlated with increased β-NTP concentrations.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Placebo-Controlled Dose-Ranging Trial of Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder: a Magnetic Resonance Spectroscopy Study
Study Start Date : June 2012
Actual Primary Completion Date : May 2014
Actual Study Completion Date : May 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Placebo Drug: Creatine monohydrate or placebo
Placebo, 2g, 4g, and 10g of creatine monohydrate

Active Comparator: 2 grams of creatine Drug: Creatine monohydrate or placebo
Placebo, 2g, 4g, and 10g of creatine monohydrate

Active Comparator: 4 grams of creatine Drug: Creatine monohydrate or placebo
Placebo, 2g, 4g, and 10g of creatine monohydrate

Active Comparator: 10 grams of creatine Drug: Creatine monohydrate or placebo
Placebo, 2g, 4g, and 10g of creatine monohydrate




Primary Outcome Measures :
  1. Brain PCr concentrations [ Time Frame: 8 weeks ]
    The primary hypothesis is that compared to placebo, 2g, 4g, and 10g of creatine monohydrate for eight weeks will be associated with a significant increase in brain phosphocreatine (PCr) concentrations.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   13 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Participants must be female.
  • Participants must be able to grant informed consent (age > 18), or parent/guardian permission plus participant assent (age < 18).
  • Participants must meet DSM-IV criteria for MDD, with current mood state depressed for > 2 weeks.
  • Participants must be between the ages of 13 and 21.
  • Current CDRS-R raw score of > 40 or MADRS score > 25; and CGI-S score > 4.
  • Participants may be enrolled in individual and/or group psychotherapy, if it has been ongoing for at least 8 weeks.
  • Participants must have been in treatment with an SSRI for at least 8 weeks, the last 4 of which were at a dosage of > or equal to 20 mg per day of fluoxetine or its equivalent, e.g. 20 mg per day of paroxetine, 20 mg citalopram, 10 mg escitalopram, or 100 mg sertraline. If the participant attempted, but could not tolerate, a dose comparable to 20 mg fluoxetine, they will be considered eligible.

Exclusion criteria:

  • Unstable co-morbid medical, neurological, or psychiatric disorder.
  • Current DSM-IV criteria for substance abuse or dependence (excepting nicotine/cigarettes).
  • Clinically significant suicidal or homicidal risk.
  • Pre-existing renal disease.
  • Proteinuria on baseline urinalysis testing.
  • Treatment with antiepileptic drugs, antipsychotic drugs, or lithium.
  • Pregnancy or breastfeeding.
  • Sexually active and unwilling to practice contraception during the study.
  • Contraindication to magnetic resonance imaging (e.g. ferromagnetic implant or claustrophobia)
  • History of hypersensitivity to creatine.
  • History of a previous failed therapeutic trial of creatine.
  • Participants may be outpatients or inpatients, but incarcerated persons will be excluded because this study is not approved for "Research Involving Prisoners."

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01601210


Locations
United States, Utah
University of Utah
Salt Lake City, Utah, United States, 84108
Sponsors and Collaborators
Perry Renshaw
Investigators
Principal Investigator: Douglas Kondo, MD University of Utah

Responsible Party: Perry Renshaw, MD, PhD, MBA, University of Utah
ClinicalTrials.gov Identifier: NCT01601210     History of Changes
Other Study ID Numbers: 00055231
First Posted: May 17, 2012    Key Record Dates
Last Update Posted: October 25, 2016
Last Verified: October 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Additional relevant MeSH terms:
Disease
Depressive Disorder
Depression
Depressive Disorder, Major
Pathologic Processes
Mood Disorders
Mental Disorders
Behavioral Symptoms